| Author/Editor | Bratkovič, Tomaž | |
| Title | Monoklonska protitelesa za preprečevanje migrene | |
| Translated title | Monoclonal antibodies for the prevention of migraine | |
| Type | članek | |
| Vol. and No. | Letnik 73, št. 2 | |
| Publication year | 2022 | |
| Volume | str. 107-114 | |
| ISSN | 0014-8229 - Farmacevtski vestnik : strokovno glasilo slovenske farmacije | |
| Language | slv | |
| Abstract | Migrena je pogosta nevrovaskularna motnja, ki močno omeji bolnikovo sposobnost opravljanja vsakodnevnih aktivnosti in zato predstavlja precejšnje zdravstveno in psihološko breme za bolnika kot tudi ekonomsko breme za družbo. Osrednji nevromodulator, vpleten v patofiziologijo migrene, je peptid, povezan z genom za kalcitonin (CGRP), ki izkazuje vazodilatorne in nociceptivne učinke. Novo skupino specifičnih zdravilnih učinkovin za preprečevanje migrene predstavljajo štiri terapevtska monoklonska protitelesa, ki vežejo bodisi CGRP ali pripadajoč receptor. Izkazujejo dobro učinkovitost in varnost, poleg tega pa jih zaradi dolge biološke razpolovne dobe apliciramo manj pogosto kot običajna sintezna protimigrenska zdravila. V prispevku predstavljamo pregled reprezentativnih kliničnih raziskav in lastnosti terapevtskih protiteles, usmerjenih proti CGRP in njegovemu receptorju.Migraine is a common neurovascular disorder that can severely affect patients’ ability to perform everyday activities, thus posing tremendous disease burden for the affected patients as well as economic burden for the society. Calcitonin gene-related peptide (CGRP), a neuropeptide with vasodilatory and pronociceptive activity, is considered the main neuromodulator involved in migraine pathophysiology. Four therapeutic monoclonal antibodies targeting either CGRP or its cognate receptor constitute a new specific prophylactic antimigraine drug group, displaying favourable efficacy and safety profiles. In addition, due to long biological half-life, monoclonal antibodies require less frequent dosing compared to conventional synthetic antimigraine drugs. here, we review the representative clinical trials and discuss the properties of therapeutic antiCGRP/CGRP-receptor antibodies. | |
| Descriptors | Migrena Klinične raziskave Nevropatije | |
| Keywords | CGRP monoklonsko protitelo učinkovitost varnost |